Companies / Neurocrine Biosciences Inc

Neurocrine Biosciences Inc

Nasdaq: NBIXCIK 914475SAN DIEGO, CAneurocrine.com ↗

Financials · FY2025

Revenue$2.86B
Net income$478.60M
Total debt—
Cash$332.40M
Diluted EPS$4.67
Shares outstanding101.6M

Ownership

101.6M shares outstanding · as of Jul 22, 2026
0.47%Insiders
Ownership
Insiders0.47%478,379
10%+ / strategic5.11%5,198,084
Institutions97.67%99,285,537
Public float0.00%0

Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 18

View all →
Insider% of sharesShares
Gorman Kevin CharlesFormerDirector
0.50%511,293
Gano KyleCEOChief Executive Officer · Director
0.15%150,815
Lyons Gary aDirector
0.12%122,141
Benevich EricChief Commercial Officer
0.06%63,190
Lippoldt DarinFormerChief Legal Officer
0.05%54,729
Rastetter William HDirector
0.04%43,678
Abernethy MattFormerChief Financial Officer
0.04%42,808
Pops Richard FDirector
0.04%37,798
Cooke JulieFormerChief Human Resources Officer
0.03%34,170
Onyia JudeChief Scientific Officer
0.03%25,670

Institutional holders 735

View all →
HolderValue% of shares
BlackRock, Inc.$2.31B13.49%
Vanguard Group Inc$1.38B9.54%
Dodge & Cox$781.21M5.42%
State Street Corporation$739.13M4.31%
JPMORGAN CHASE & CO$737.57M5.12%
AQR Capital Management, LLC$650.66M4.86%
Two Sigma Investments, LP$403.20M3.01%
Renaissance Technologies LLC$318.67M2.38%
Geode Capital Management, LLC$280.80M2.10%
Wellington Management Group LLP$247.43M1.72%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
May 19, 2026Gorman Kevin Charles
Director
SellCommon Stock$37.82M-245K
-32.40%
511,293
0.50% of shares
high
May 19, 2026Gorman Kevin Charles
Director
ExerciseCommon Stock$8.87M+205K
+37.20%
756,381
0.74% of shares
low
Jan 16, 2026Gano Kyle
CEO
SellCommon Stock$4.59M-35K
-19.77%
140,407
0.14% of shares
medium
Feb 13, 2026Gorman Kevin Charles
Director
OtherCommon Stock$4.27M-34K
-5.87%
551,293
0.54% of shares
low
May 15, 2026Pops Richard F
Director
SellCommon Stock$2.36M-15K
-30.32%
34,480
0.03% of shares
medium
Feb 13, 2026Delaet Ingrid
Executive
OtherCommon Stock$1.33M-11K
-39.86%
16,225
0.02% of shares
low
Feb 13, 2026Onyia Jude
Executive
OtherCommon Stock$1.33M-11K
-27.20%
28,780
0.03% of shares
low
Jun 5, 2026Sherwin Stephen a
Director
SellCommon Stock$1.29M-8K
-19.29%
32,977
0.03% of shares
medium

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A—0—
JPMORGAN CHASE & COPassive13G—5,198,084—

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
NBIX——64125C109—